Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

Core Insights - AnaptysBio, Inc. is participating in TD Cowen's 44th Annual Health Care Conference and will present at the 2024 American Academy of Dermatology Annual Meeting, focusing on its preclinical data for ANB032, a BTLA agonist targeting atopic dermatitis [1][2][3] Group 1: Conference Participation - The company will engage in a corporate panel discussion titled "Inflammation & Immunology Corporate Panel Discussion" on March 5, 2024, at 2:10 PM ET [2] - A live webcast of the panel discussion will be available on the investor section of the AnaptysBio website, with a replay accessible for at least 30 days post-event [2] Group 2: Upcoming Presentations - AnaptysBio will present oral and poster presentations on ANB032, highlighting its role in modulating dendritic cell maturation and function as a novel mechanism for addressing atopic dermatitis [3] - The presentation is scheduled for March 8, 2024, from 9:30 AM PT to 9:35 AM PT, under the category of Dermatitis, Atopic [3] Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics, developing immune cell modulators including PD-1 and BTLA agonists for autoimmune and inflammatory diseases [4] - The company is advancing multiple candidates, including rosnilimab in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032 in Phase 2b trials for atopic dermatitis [4] - AnaptysBio has also developed cytokine antagonists for out-licensing and has collaborations with GSK for immuno-oncology therapeutic antibodies [4]